核医学と放射線治療

Bone-Seeking Targeted Radio-Nuclide Therapy BT-RNT) in Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC): Shifting from Palliation to Improving Survival

Abstract

Vimoj J Nair, Colin Malone, Patricia Moretto, Eugene Leung and Shawn Malone

Background: The purpose of this article is to review the role of bone-seeking targeted radionuclide therapy (BT-RNT) in metastatic prostate cancer. The mechanisms of actions, radiobiology and clinical benefits of BT-RNTs will be reviewed.

Methods: Relevant studies of CRPC and targeted therapies were identified from literature and clinical trial databases, websites, and conference abstracts.

Results: BT-RNT in mCRPC has a proven beneficial palliative role in treatment of patients with mCRPC. The use of these agents as a monotherapy as well as combination with other palliative therapies are evolving. Among the various BT-RNT’s the alpha emitter ²²³Ra which is highly targeted and well tolerated has shown significant clinical benefit and survival advantage in this patient population.

Conclusion: BT-RNT represents an exciting treatment option for patients with mCRPC. ²²³Ra represents a new treatment paradigm for patients with mCRPC.